Showing 1951-1960 of 2526 results for "".
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-36-months-in-phase-2b-study/2480567/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 36-month analysis of the phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. <
- Reichert Technologies Celebrates 100 Years of Phoroptorhttps://modernod.com/news/reichert-technologies-celebrates-100-years-of-phoroptor/2480561/Reichert Technologies is celebrating 100 years of the Phoroptor. On January 10, 1922, the United States Patent & Trademark Office granted a registered trademark to the word "Phoroptor" to coincide with its first model release. Ever since, Phoroptor has been synonymous with vision ca
- Regenxbio Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Deliveryhttps://modernod.com/news/regenxbio-announces-initiation-of-second-pivotal-trial-in-rgx-314-clinical-program-for-the-treatment-of-wet-amd-using-subretinal-delivery/2480556/Regenxbio announced the initiation of ASCENT, the second of two phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration (AMD). ASCENT, the first trial to be initiated by Regenxbio under the e
- Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division with Acquisition of Warden Biohttps://modernod.com/news/kriya-expands-gene-therapy-pipeline-and-establishes-its-rare-disease-therapeutic-area-division-with-the-acquisition-of-warden-bio/2480550/Gene therapy company Kriya Therapeutics announced that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs.</
- New Survey From Bausch + Lomb and Glaucoma Research Foundation Reveals Emotional and Social Impact of Hyperemia on Glaucoma Patientshttps://modernod.com/news/new-survey-from-bausch-lomb-and-glaucoma-research-foundation-reveals-emotional-and-social-impact-of-hyperemia-on-glaucoma-patients/2480542/Bausch + Lomb and Glaucoma Research Foundation (GRF) released new key findings from a survey of glaucoma patients that was designed to gain a greater understanding of the impact that hyperemia can have in the treatment and lives of people living with glaucoma. In the Unit
- Global Data: Primary Open Angle Glaucoma Total Prevalent Cases to Reach 8.84 Million by 2030https://modernod.com/news/global-data-primary-open-angle-glaucoma-total-prevalent-cases-to-reach-884-million-by-2030/2480534/The burden of total prevalent cases (diagnosed and undiagnosed) of primary open angle glaucoma (POAG) is expected to increase at an annual growth rate (AGR) of 2% from around 7.3 million cases in 2020 to 8.84 million in 2030 in the seven major markets, according to GlobalData. The increase is par
- Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-in-china-screened-in-the-ongoing-ncx-470-denali-phase-3-trial-in-glaucoma/2480521/Nicox SA announced that the first patient has been screened in China in the ongoing Denali phase 3 clinical trial, opening the way for new drug application (NDA) submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma. Denali, wh
- LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platformhttps://modernod.com/news/layerbio-granted-us-patent-for-ocuring-drug-delivery-platform/2480486/LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441. "This patent issuance marks an important milestone for the OcuRing platform and recognition of novelty and uniqueness of our drug delivery technology,&
- Visus Therapeutics Announces Positive Topline Clinical Data from Phase 2 VIVID Study of Brimochol for the Treatment of Presbyopiahttps://modernod.com/news/visus-therapeutics-announces-positive-topline-clinical-data-from-phase-2-vivid-study-of-brimochol-for-the-treatment-of-presbyopia/2480481/Visus Therapeutics reported positive topline results from VIVID, the company’s phase 2 study of three novel topical ophthalmic formulations under investigation for the treatment of presbyopia. All three investigational candidates studied in VIVID achieved the endpoint of 3 lines of improvem
- Santen to Introduce First Plant-Derived Eye Drop Bottle in EMEA to Help Reduce Reliance on Fossil Fuel-Based Plastichttps://modernod.com/news/santen-to-introduce-first-plant-derived-eye-drop-bottle-in-emea-to-help-reduce-reliance-on-fossil-fuel-based-plastic/2480457/Santen unveiled plans to launch t